Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.

Trial Details

NCT ID
NCT04047953
Phase
NA
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age of 18-75 years; male or female.
  • Karnofsky Performance Status Score ≥70.
  • Histological diagnosis of gastric adenocarcinoma, HER2 expression negative.
  • The initial unresectable locally advanced or potentially resectable metastatic gastric adenocarcinoma, potentially resectable factor includes a sin…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →